Patients with type 2 diabetes mellitus who were suspected as having ischemic heart disease
Conditions
Interventions
Alogliptin
Sponsors
Kanagawa PTCA Conference
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patients with type 2 diabetes mellitus(2)Patients as having mild atherosclerosis (diameter stenosis less than 50%) evaluated by CCTA at baseline (3)Patients who are judged by physician to administrate alogliptin
Exclusion criteria
Exclusion criteria: (1)Patients who are suspected as having significant stenosis evaluated by CCTA and require to receive percutaneous coronary intervention (PCI) (2)Patients with acute coronary syndrome within 30 days (3)Patients with the past history of PCI(4)Patients with post coronary artery bypass grafting (CABG) (5)Patients with complex congenital heart disease (6)Patients with body mass index >35kg/m2 (7)Patients with the past history of heart failure (8)Patients with the past history of ketoacidosis or diabetic coma (9)Patients with hepatic disorder or with AST (GOT) or ALT (GPT) greater than 2 times of the upper limits of normal (10)Patients with renal dysfunction (estimated glomerular filtration rate 30 ml/min/1.73m2 or lower) (11)Patients with severe infection, pre or post operation, or severe trauma (12)Patients with a history of hypersensitivity to any of the components of alogliptin (13)Pregnant women, women suspected of being pregnant, or lactating women (14)Patients ineligible for the study determined by physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of FFR evaluated by CCTA (FFRCT) | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in plaque volume evaluated by CCTA Change in CT values evaluated by CCTA | — |
Countries
Japan
Contacts
Public ContactTsuyoshi Nozue
Yokohama Sakae Kyosai Hospital Division of Cardiology, Department of Internal Medicine
Outcome results
None listed